(Q46817711)

25 December 2017

title

Asthma-related health care resource use among patients starting fluticasone or montelukast therapy (English)

1 reference

25 December 2017

4

Leona E Markson

1 reference

25 December 2017

Felicia C Allen-Ramey

series ordinal

1

object named as

Felicia C Allen-Ramey

1 reference

25 December 2017

Shiva G Sajjan

series ordinal

3

object named as

Shiva G Sajjan

1 reference

25 December 2017

author name string

David T Anstatt

series ordinal

2

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

25 December 2017

published in

Pharmacotherapy

1 reference

25 December 2017

volume

25

1 reference

25 December 2017

issue

12

1 reference

25 December 2017

page(s)

1752-1760

1 reference

25 December 2017

Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

Systematic reviews and lifelong diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

Database studies in asthma pharmacoeconomics: uses, limitations and quality markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

"Real-world" effectiveness of daily controller medicine in children with mild persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

The risk of hospitalization in patients with asthma switched from an inhaled corticosteroid to a leukotriene receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

National trends in asthma visits and asthma pharmacotherapy, 1978-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

Long-term effects of budesonide or nedocromil in children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

The central role of the propensity score in observational studies for causal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1752

10.1592/PHCO.2005.25.12.1752

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017